Conn’s (NASDAQ:CONN) reported quarterly earnings of $0.04 per share which missed the analyst consensus estimate of $0.09 by 55.56 percent. This is a 96.72 percent decrease over earnings of $1.22 per share from the same period last year. The company reported quarterly sales of $346.60 million which missed the analyst consensus estimate of $370.23 million by 6.38 percent. This is a 17.16 percent decrease over sales of $418.38 million the same period last year.
AstraZeneca Announced Enhertu Granted Priority Review in the US for Patients with HER2-low Metastatic Breast Cancer
AstraZeneca and Daiichi Sankyo have received notification of acceptance of the supplemental Biologics License Application (sBLA) of Enhertu (trastuzumab deruxtecan) for the treatment of adult patients in the US with unresectable or metastatic HER2-low (immunohistochemistry [IHC] 1+ or IHC 2+/in-situ hybridisation [ISH]-negative) breast cancer who have received a prior therapy in the metastatic set
